IRAK1 and type 1 diabetes mellitus: Moreover, we discovered that IL-2 therapy directly inhibits SRA, and our findings partially reconcile observations that IL-2 can inhibit T1D progression through anti-SRA-mediated, IRAK1/LDHA/lactate-dependent mechanisms (Figure 7).